Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

On this weeks Business of Biotech, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet ...

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

Explore the implications of the newly enacted "One Big Beautiful Bill" and how it will alleviate the administrative burdens faced by clinical research stakeholders and benefit low-income ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

Crystalline forms of compounds and salts are frequently claimed in chemical patents, including in pharmaceuticals and agrochemicals. Different crystalline forms of the same substance — that is, ...

<p>On this week&#39;s episode, Roger Cone, Ph.D., Founder and Chair of the Scientific Advisory Board at Courage Therapeutics, talks about discovering obesity-related protein receptors in the brain, ...